BioSpace News Archive

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, highlighted the company’s key 2024 milestones ahead of its presentation at J.P. Morgan’s 42nd annual healthcare conference.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601, a potentially best-in-class TGFβ blocking monoclonal antibody targeting the integrin αvβ8.

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced initiation of enrollment in the combination arm of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11.

Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Oncolytics Biotech® Inc. today announced the appointment of Patricia S. Andrews to its Board of Directors (the “Board”).

Renibus Therapeutics® today announced publication in E-Clinical Medicine, part of The Lancet Discovery Science, of results from the Phase 2 study evaluating RBT-1, the Company’s first-in-a-new-class preconditioning agent, under investigation to reduce post-operative complications following cardiothoracic surgery.

Sonendo, Inc. announced a partnership agreement with Dental Purchasing Group, a member-driven group purchasing organization that provides independent and group dental practices with cost savings programs.

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced encouraging new data from an ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab).

McKesson to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

Endologix LLC is pleased to announce that Scott Ward has been appointed to the Endologix Board of Directors.